Collagen-producing eye cell atlas reveals distinct fibroblast fates in early injury vs. fibrotic subretinal disease

E Ema Ozaki (Department of Clinical Medicine, School of Medicine, Trinity College Dublin) S Said Aktas (Pharma Research and Early Development, Roche Innovation Center Zurich, Roche Glycart AG.) K Kelly Mulfaul (Department of Neuroscience and Pharmacology, University of Iowa) K Kiva Brennan (Department of Clinical Medicine, School of Medicine, Trinity College Dublin) C Christophe Roubeix (Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.) S Sarah Palko (Department of Clinical Medicine, School of Medicine, Trinity College Dublin) K Katie Robb (Department of Clinical Medicine, School of Medicine, Trinity College Dublin) T Tai-Hsien Ou Yang (Roche Pharma Research and Early Development, Data and Analytics, Roche Translational & Clinical Research Center, F. Hoffmann-La Roche Ltd.) M Marie-Claire Schanne-Klein (Laboratoire d’Optique et Biosciences, Ecole Polytechnique, CNRS, INSERM, Institut Polytechnique de Paris) A Anna Toidze (Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.) A Avril Watson (Department of Clinical Medicine, School of Medicine, Trinity College Dublin) M Mark Cahill (Progressive Vision Research) P Peter D. Westenskow (Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.) D Derrick Feenstra (Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.) S Sarah L. Doyle (Department of Clinical Medicine, School of Medicine, Trinity College Dublin)

Abstract

Fibrosis is the end-stage of a maladaptive process that occurs when the body’s normal wound-healing strategy becomes dysregulated. Subretinal fibrosis is the end stage of neovascular age-related macular degeneration (nAMD), the most common cause of central vision loss in people over the age of 50. The cellular sources of excess extracellular matrix (ECM) contributing to subretinal fibrosis are unknown, as is the heterogeneity of cells involved in the fibrotic process. Here we identify cells contributing to subretinal fibrosis by using Col1a1 -YFP reporter mice to noninvasively image collagen production in real-time in vivo in two disease models, 1) a resolving retinal injury model and 2) a fibrotic model of subretinal disease. We create a collagen-producing eye cell atlas for subretinal injury and demonstrate subretinal fibroblast heterogeneity in healthy, resolving, and fibrotic tissue. We identify distinct molecular characteristics of general repair/resolving fibroblast populations versus pathogenic pro-fibrotic collagen-producing fibroblasts. Integration of this collagen-producing eye cell atlas with a published collagen-producing lung cell atlas shows conserved pro-fibrotic fibroblasts in both organs, yet also uncovers tissue-specific fibroblast populations unique to subretinal fibrosis. A Fap + Fgl2 + fibroblast population significantly expands in subretinal fibrosis that expresses the highest levels of collagens and distinctively expresses ECM components Periostin , Col15a1 and Col6a5 . Immunolabeling of mouse and human-donor eye tissue support the fibroblastic expression and perivascular location of periostin as clearly distinguishing between bona fide fibrosis and early disease in nAMD. Our collagen-producing eye cell atlas is a valuable resource for studying distinct fibroblast subsets in homeostasis, early injury, and fibrosis.

Article Details

Volume / Issue Vol. 123, Issue 26
Published June 30, 2026
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (15)

E

Ema Ozaki

Department of Clinical Medicine, School of Medicine, Trinity College Dublin

S

Said Aktas

Pharma Research and Early Development, Roche Innovation Center Zurich, Roche Glycart AG.

K

Kelly Mulfaul

Department of Neuroscience and Pharmacology, University of Iowa

K

Kiva Brennan

Department of Clinical Medicine, School of Medicine, Trinity College Dublin

C

Christophe Roubeix

Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.

S

Sarah Palko

Department of Clinical Medicine, School of Medicine, Trinity College Dublin

K

Katie Robb

Department of Clinical Medicine, School of Medicine, Trinity College Dublin

T

Tai-Hsien Ou Yang

Roche Pharma Research and Early Development, Data and Analytics, Roche Translational & Clinical Research Center, F. Hoffmann-La Roche Ltd.

M

Marie-Claire Schanne-Klein

Laboratoire d’Optique et Biosciences, Ecole Polytechnique, CNRS, INSERM, Institut Polytechnique de Paris

A

Anna Toidze

Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.

A

Avril Watson

Department of Clinical Medicine, School of Medicine, Trinity College Dublin

M

Mark Cahill

Progressive Vision Research

P

Peter D. Westenskow

Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.

D

Derrick Feenstra

Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.

S

Sarah L. Doyle

Department of Clinical Medicine, School of Medicine, Trinity College Dublin